Floatz logo

VERAPAMIL SLOW RELEASE

Hypoglycemia

Zealand University HospitalSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Hypoglycemia cohort.

Asset / SponsorPhaseRating
Liraglutide
Zealand University Hospital
Phase 4BB
Sitagliptin
Zealand University Hospital
Phase 4BB
Empagliflozin
Insel Gruppe AG, University Hospital Bern
Phase 4BB
Acarbose
Zealand University Hospital
Phase 4BB
Pasireotide
Zealand University Hospital
Phase 4B

View all 10 →

Same molecule, other indications

VERAPAMIL SLOW RELEASE is also rated in:

hypertensive disorderDormant
BBB
Indicative ·
72 / 100
View asset →
Vestibular MigraineDormant
BB
Indicative ·
67 / 100
View asset →
obesity disorderDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →